Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)

Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki

Research output: Contribution to journalArticle

Abstract

Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9–14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date. The exosome-focused translational research for afatinib (EXTRA) study aims to identify a novel predictive biomarker and a resistance marker for afatinib by analyzing data from association studies of the clinical efficacy of afatinib and four “OMICs” (genomics, proteomics, epigenomics, and metabolomics) using peripheral blood from patients treated with afatinib. This study aims to: (i) conduct comprehensive multi-OMIC analyses in a prospective clinical trial, and (ii) focus on both sera/plasma and exosome as a source for OMIC analyses to identify a novel predictor of the efficacy of a specific drug. To eliminate the carryover bias of prior treatment, systemic treatment-naïve patients were enrolled. The candidates to be screened for biomarkers comprise a discovery cohort of 60 patients and an independent validation cohort of 40 patients. The EXTRA study is the first trial to screen novel biomarkers of longer treatment efficacy of EGFR-TKIs using four-OMICs analyses, focusing on both “naked or free” molecules and “capsulated” exosomal components in serially collected peripheral blood.

Original languageEnglish
JournalThoracic Cancer
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Exosomes
Translational Medical Research
Non-Small Cell Lung Carcinoma
Biomarkers
Protein-Tyrosine Kinases
Metabolomics
Genomics
Epigenomics
Proteomics
Disease-Free Survival
Therapeutics
BIBW 2992
Clinical Trials
Serum
Pharmaceutical Preparations

Keywords

  • Afatinib
  • epidermal growth factor receptor
  • exosome
  • OMIC
  • translational research

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). / Okuma, Yusuke; Morikawa, Kei; Tanaka, Hisashi; Yokoyama, Takuma; Itani, Hidetoshi; Horiuchi, Kazuya; Nakagawa, Hideyuki; Takahashi, Nobumasa; Bessho, Akihiro; Soejima, Kenzo; Kishi, Kazuma; Togashi, Akira; Kanai, Yae; Ueda, Koji; Horimoto, Katsuhisa; Matsutani, Noriyuki; Seki, Nobuhiko.

In: Thoracic Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Okuma, Y, Morikawa, K, Tanaka, H, Yokoyama, T, Itani, H, Horiuchi, K, Nakagawa, H, Takahashi, N, Bessho, A, Soejima, K, Kishi, K, Togashi, A, Kanai, Y, Ueda, K, Horimoto, K, Matsutani, N & Seki, N 2018, 'Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)', Thoracic Cancer. https://doi.org/10.1111/1759-7714.12923
Okuma, Yusuke ; Morikawa, Kei ; Tanaka, Hisashi ; Yokoyama, Takuma ; Itani, Hidetoshi ; Horiuchi, Kazuya ; Nakagawa, Hideyuki ; Takahashi, Nobumasa ; Bessho, Akihiro ; Soejima, Kenzo ; Kishi, Kazuma ; Togashi, Akira ; Kanai, Yae ; Ueda, Koji ; Horimoto, Katsuhisa ; Matsutani, Noriyuki ; Seki, Nobuhiko. / Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). In: Thoracic Cancer. 2018.
@article{c886fcc297a14a54b8336a3afe30b31b,
title = "Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)",
abstract = "Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9–14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date. The exosome-focused translational research for afatinib (EXTRA) study aims to identify a novel predictive biomarker and a resistance marker for afatinib by analyzing data from association studies of the clinical efficacy of afatinib and four “OMICs” (genomics, proteomics, epigenomics, and metabolomics) using peripheral blood from patients treated with afatinib. This study aims to: (i) conduct comprehensive multi-OMIC analyses in a prospective clinical trial, and (ii) focus on both sera/plasma and exosome as a source for OMIC analyses to identify a novel predictor of the efficacy of a specific drug. To eliminate the carryover bias of prior treatment, systemic treatment-na{\"i}ve patients were enrolled. The candidates to be screened for biomarkers comprise a discovery cohort of 60 patients and an independent validation cohort of 40 patients. The EXTRA study is the first trial to screen novel biomarkers of longer treatment efficacy of EGFR-TKIs using four-OMICs analyses, focusing on both “naked or free” molecules and “capsulated” exosomal components in serially collected peripheral blood.",
keywords = "Afatinib, epidermal growth factor receptor, exosome, OMIC, translational research",
author = "Yusuke Okuma and Kei Morikawa and Hisashi Tanaka and Takuma Yokoyama and Hidetoshi Itani and Kazuya Horiuchi and Hideyuki Nakagawa and Nobumasa Takahashi and Akihiro Bessho and Kenzo Soejima and Kazuma Kishi and Akira Togashi and Yae Kanai and Koji Ueda and Katsuhisa Horimoto and Noriyuki Matsutani and Nobuhiko Seki",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/1759-7714.12923",
language = "English",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",

}

TY - JOUR

T1 - Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)

AU - Okuma, Yusuke

AU - Morikawa, Kei

AU - Tanaka, Hisashi

AU - Yokoyama, Takuma

AU - Itani, Hidetoshi

AU - Horiuchi, Kazuya

AU - Nakagawa, Hideyuki

AU - Takahashi, Nobumasa

AU - Bessho, Akihiro

AU - Soejima, Kenzo

AU - Kishi, Kazuma

AU - Togashi, Akira

AU - Kanai, Yae

AU - Ueda, Koji

AU - Horimoto, Katsuhisa

AU - Matsutani, Noriyuki

AU - Seki, Nobuhiko

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9–14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date. The exosome-focused translational research for afatinib (EXTRA) study aims to identify a novel predictive biomarker and a resistance marker for afatinib by analyzing data from association studies of the clinical efficacy of afatinib and four “OMICs” (genomics, proteomics, epigenomics, and metabolomics) using peripheral blood from patients treated with afatinib. This study aims to: (i) conduct comprehensive multi-OMIC analyses in a prospective clinical trial, and (ii) focus on both sera/plasma and exosome as a source for OMIC analyses to identify a novel predictor of the efficacy of a specific drug. To eliminate the carryover bias of prior treatment, systemic treatment-naïve patients were enrolled. The candidates to be screened for biomarkers comprise a discovery cohort of 60 patients and an independent validation cohort of 40 patients. The EXTRA study is the first trial to screen novel biomarkers of longer treatment efficacy of EGFR-TKIs using four-OMICs analyses, focusing on both “naked or free” molecules and “capsulated” exosomal components in serially collected peripheral blood.

AB - Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9–14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date. The exosome-focused translational research for afatinib (EXTRA) study aims to identify a novel predictive biomarker and a resistance marker for afatinib by analyzing data from association studies of the clinical efficacy of afatinib and four “OMICs” (genomics, proteomics, epigenomics, and metabolomics) using peripheral blood from patients treated with afatinib. This study aims to: (i) conduct comprehensive multi-OMIC analyses in a prospective clinical trial, and (ii) focus on both sera/plasma and exosome as a source for OMIC analyses to identify a novel predictor of the efficacy of a specific drug. To eliminate the carryover bias of prior treatment, systemic treatment-naïve patients were enrolled. The candidates to be screened for biomarkers comprise a discovery cohort of 60 patients and an independent validation cohort of 40 patients. The EXTRA study is the first trial to screen novel biomarkers of longer treatment efficacy of EGFR-TKIs using four-OMICs analyses, focusing on both “naked or free” molecules and “capsulated” exosomal components in serially collected peripheral blood.

KW - Afatinib

KW - epidermal growth factor receptor

KW - exosome

KW - OMIC

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=85058164168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058164168&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.12923

DO - 10.1111/1759-7714.12923

M3 - Article

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

ER -